Who are EGb 761® (Tanakan®)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ginkgo Biloba Extract (GBE), Ginkgo biloba standardized extract 24/6.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/egb-761-tanakan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

EGb 761® (Tanakan®) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EGb 761® (Tanakan®) (EGb 761® (Tanakan®)) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Herbal extract / Nootropic. Area: Neurology / Cardiovascular.

marketed Herbal extract / Nootropic Neurology / Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

EGb 761® (Tanakan®) (EGb 761® (Tanakan®)) — Ipsen. EGb 761 is a standardized Ginkgo biloba extract that improves blood flow and reduces oxidative stress in the brain and peripheral tissues.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
EGb 761® (Tanakan®) TARGET	EGb 761® (Tanakan®)	Ipsen	marketed	Herbal extract / Nootropic
Ginkgo Biloba Extract (GBE)	Ginkgo Biloba Extract (GBE)	Taipei Veterans General Hospital, Taiwan	marketed	Herbal extract / Nootropic
Ginkgo biloba standardized extract 24/6	Ginkgo biloba standardized extract 24/6	Milsing d.o.o.	marketed	Herbal extract / Nootropic

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Herbal extract / Nootropic class)

Ipsen · 1 drug in this class
Milsing d.o.o. · 1 drug in this class
Taipei Veterans General Hospital, Taiwan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EGb 761® (Tanakan®) — Competitive Intelligence Brief. https://druglandscape.com/ci/egb-761-tanakan. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab